Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046



Plasma nitrite/nitrate concentrations in patients with schizophrenia

Vladimir V. Djordjević1 / Ivana Stojanović2 / Dragana Stanković-Ferlež3 / Tatjana Ristić3 / Dušan Lazarević4 / Vladan Ćosić3 / Vidosava B. Djordjević2

1Clinic for Mental Health Protection, Clinical Centre Niš, Niš, Serbia

2Institute of Biochemistry, Faculty of Medicine, Niš, Serbia

3Centre for Medical Biochemistry, Clinical Centre Niš, Niš, Serbia

4Clinic for Psychiatry, Clinical Centre Niš, Niš, Serbia

Corresponding author: Prof. Dr. Vidosava B. Djordjević, PhD, Institute of Biochemistry, Faculty of Medicine, Bul. dr Zorana Djindjića 81, 18000 Niš, Serbia

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Issue 1, Pages 89–94, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.014, January 2010

Publication History



Background: Nitric oxide (NO) is known to be a signaling molecule with many physiogical functions including apoptotic process regulation. Since apoptosis may contribute to the pathophysiology of schizophrenia, this study was undertaken to determine the plasma concentrations of NO in schizophrenics.

Methods: Nitrite/nitrate (NO2/NO3) concentrations were measured in plasma from 40 patients with schizophrenia, and 36 age- and gender-matched healthy persons using a colorimetric test.

Results: Plasma NO2/NO3 concentrations were significantly higher in patients with schizophrenia (102.8±34.7 μmol/L, p<0.0001) than in controls (69.2±13.2 μmol/L). Also, mean NO2/NO3 values in female patients and controls were significantly higher (118.2±44.7 μmol/L, p<0.001; 74.8±16.1 μmol/L, p<0.05, respectively) compared to males (94.7±25.3 μmol/L, 67.6±10.8 μmol/L). Significant correlation was seen between plasma NO2/NO3 concentrations and heredity, number of episodes and peripheral blood mononuclear cell (PBMC) caspase-3 activity, which was significantly higher in patients than in controls (p<0.05). There was no significant difference in NO2/NO3 concentrations between patients with different Positive and Negative Syndrome Scale (PANSS) scores or between patients treated with haloperidol (97.2±31.2 μmol/L) and those treated with other atypical antipsychotic drugs (109.8±33.7 μmol/L). Both parameters showed no significant differences between smokers and non-smokers.

Conclusions: This study showed that plasma NO2/NO3 concentrations were significantly increased in patients with schizophrenia, being significantly higher in female than male patients, and showing a significant correlation with heredity, number of episodes and PBMC caspase-3 activity. These results suggest that NO could be considered an inducer or regulator of apoptosis in patients with schizophrenia.

Clin Chem Lab Med 2010;48:89–94.

Keywords: caspase-3 activity; nitrite/nitrate; schizophrenia

Comments (0)

Please log in or register to comment.